Premium
Atypical neuroleptic malignant syndrome with long‐acting paliperidone
Author(s) -
Lam Y. W. Francis
Publication year - 2016
Publication title -
the brown university psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7532
pISSN - 1068-5308
DOI - 10.1002/pu.30183
Subject(s) - neuroleptic malignant syndrome , medicine , clozapine , adverse effect , antipsychotic , paliperidone , cardiology , anesthesia , schizophrenia (object oriented programming) , psychiatry
Neuroleptic malignant syndrome (NMS) is a rare but serious and potentially fatal adverse effect caused by dopamine receptor blockade associated with the use of antipsychotic agents. The incidence of NMS has been estimated to range from 0.01% to 2.4%, and the syndrome can occur in any age group, including the elderly. Classical features include mental status changes, muscular rigidity, hyperthermia, and symptoms suggestive of autonomic instability (e.g., presyncope, tachycardia, diaphoresis), with elevated creatine kinase and white blood cell count as common laboratory findings.